- cafead   May 23, 2024 at 09:52: PM
via For the first time, investigators have revealed clinical trial performance for a triplet containing Bristol Myers’ PD-1/LAG-3 combo Opdualag and the CTLA4 inhibitor Yervoy in advanced melanoma. The three-drug regimen shrank tumors in 27 of 46 first-line melanoma patients.
article source
article source